MYCN and metastatic neoplasm: However, the decision to treat patients on national high-risk protocols varies, e.g. in most of Europe, HRNB is defined as patients over 12 months with metastatic disease, MYCN amplified localised unresectable disease and infants with MYCN amplified metastatic disease [1].